Leukemia
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor (J2N-MC-JZNX)
- Details
ClinicalTrials.gov ID:
NCT06588478
Diagnosis Type:
NA
USOR Number:
- Address
,
P: